Breaking News From Pharma & Bio Ingredients
Technology Milestone for PER.C6
Posted on 2008-03-11 07:16:00
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. announced another milestone for the PER.C6 technology platform for the production of monoclonal antibodies and recombinant proteins. Scientists working at PERCIVIA reached a record level titer of 15 g/L at harvest for an antibody product. PERCIVIA is the PER.C6® Development Center joint venture between DSM and Crucell, located in Cambridge, MA.
Crucell's PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6 technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.
Marco Cacciuttolo, CEO of PERCIVIA comments, “This high titer achievement for PER.C6, the highest reported to date, marks a major event for the biopharmaceutical industry. It demonstrates the power and robustness of the PER.C6 manufacturing platform and it clearly shows that the PER.C6 manufacturing platform will have a major impact to the overall economics of manufacturing biopharmaceuticals. DSM and Crucell recognized the enormous potential of the PER.C6 technology when starting the PERCIVIA joint venture just over 1 year ago. The breakthrough results achieved in a single year reinforce the special properties and abilities of the PER.C6 manufacturing platform. Based on our scientific data today, we are confident that we will be able to drive productivity even further.”
Subscribe via RSS
